Review

Rutin (Bioflavonoid) as Cell Signaling Pathway Modulator: Prospects in Treatment and Chemoprevention

Pratibha Pandey 1,†, Fahad Khan 1,*,†, Huda A. Qari 2 and Mohammad Oves 3,*

Abstract: Cancer is a complex ailment orchestrated by numerous intrinsic and extrinsic pathways. Recent research has displayed a deep interest in developing plant-based cancer therapeutics for better management of the disease and limited side effects. A wide range of plant-derived compounds have been reported for their anticancer potential in the quest of finding an effective therapeutic approach. Rutin (vitamin P) is a low-molecular weight flavonoid glycoside (polyphenolic compound), abundantly present in various vegetables, fruits (especially berries and citrus fruits), and medicinal herbs. Numerous studies have delineated several pharmacological properties of rutin such as its antiprotozoal, antibacterial, anti-inflammatory, antitumor, antiviral, antiallergic, vasoactive, cytoprotective, antispasmodic, hypolipidemic, antihypertensive, and antiplatelet properties. Specifically, rutin-mediated anticancerous activities have been reported in several cancerous cell lines, but the most common scientific evidence, encompassing several molecular processes and interactions, including apoptosis pathway regulation, aberrant cell signaling pathways, and oncogenic genes, has not been thoroughly studied. In this direction, we attempted to project rutin-mediated oncogenic pathway regulation in various carcinomas. Additionally, we also incorporated advanced research that has uncovered the notable potential of rutin in the modulation of several key cellular functions via interaction with mRNAs, with major emphasis on elucidating direct miRNA targets of rutin as well as the process needed to transform these approaches for developing novel therapeutic interventions for the treatment of several cancers.

Keywords: rutin; therapeutic potential; cancer; cell signaling pathways; miRNA

1. Introduction

Cancer is a multifactorial ailment with an entangled cell landscape highlighted by a chain of complex molecular mechanisms and interactions. Advancements in proteomic- and genomic-based approaches have made it possible to unveil the tumor microenvironment in order to gain a better insight into key mechanisms such as overexpression, gene suppression, altered cellular signaling pathways, genomic instability, and mutations at the genetic/epigenetic level within the genetic framework involved in cancer progression [1,2].

Accumulating evidence has led to plant extract-based formulations and compounds gaining special attention in the management of several malignancies including cancer, neurodegenerative disorders, cardiovascular diseases, and diabetes [3,4]. Further, they have displayed significant potential in modulating the expression of chief signaling pathways associated with cancer progression [5–8]. Numerous plant-based chemotherapeutic drugs have displayed significant increases in the anticancer efficacies of numerous chemotherapeutic agents, including vinblastine, doxorubicin, camptothecin, and paclitaxel [9–11].
Plant metabolites have displayed pleiotropic efficacies, and they target numerous cancer hallmarks such as inflammation, angiogenesis, cancer cell growth and proliferation, invasion, migration, and metastasis [12–14].

The name rutin (green-yellow-colored, needle-shaped crystal) originates from Ruta graveolens L., a plant that is rich in rutin. Rutin has also been named rutoside, vitamin P, quercetin-3-O-rutinoside, and sophorin, with the chemical formula, C_{27}H_{30}O_{16} and a molecular weight of 610.53. The natural sources of rutin are fruits, medicinal herbs, and plants (Figure 1A,B).

![Structure and dietary sources of rutin (bioflavonoid): (A) structure and (B) dietary sources.](image)

**Figure 1.** Structure and dietary sources of rutin (bioflavonoid): (A) structure and (B) dietary sources.

Rutin can be considered a safe anticancerous agent with very few or limited side effects (such as MDR (multiple drug resistance)) and limitations (high cost) in comparison to other cancer therapies including surgery, stem cell therapy, radiotherapy, chemo/immunotherapies, and photodynamic therapy [15–19]. This has further motivated us to comprehensively cover the therapeutic potential of rutin in tumor proliferation and invasiveness leading to apoptotic induction in cancerous cells. Rutin is a naturally occurring bioflavonoid abundantly reported in medicinal herbs, fruits, vegetables, and plant-based beverages. Research has further presented the in vitro potential of rutin in the suppression of numerous human cancers such as lung cancer, prostate cancer, colorectal cancer, breast cancer, liver cancer, glioblastoma, melanoma, osteosarcoma, ovarian cancer, leukemia, cervical cancer, and pancreatic cancer via apoptosis induction, immunity enhancement, or cell migration knockdown, which leads to a significant reduction in the motility rate of cancerous cells [20–24].

### 2. Anticancerous Therapeutic Potential of Rutin

Rutin has been reported to counteract numerous cancers via several mechanisms such as cell cycle arrest, inflammation, malignant cell growth inhibition, oxidative stress, apoptosis induction, and angiogenesis modulation, and all of these are mediated through the regulation of cellular signaling pathways. Several in vitro studies have reported the significant anticancerous potential of rutin via its inhibition of the proliferation of several cancer types including glioma, breast, liver, pancreas, colon, lung, prostate, skin, ovarian, and cervical cancer (Table 1).
Table 1. In vitro antitumor efficacy of rutin and its mechanisms of action.

| Cancer            | Cell Lines      | Doses      | Anticancer Mechanism                                           | Molecular Targets         | References          |
|-------------------|-----------------|------------|---------------------------------------------------------------|---------------------------|---------------------|
| Lung cancer       |                 |            |                                                              |                           |                     |
|                   | A549            | 20–560 µM  | Cell growth, invasion, and adhesion inhibition; apoptosis and autophagy induction | p38, NF-κB, TNF-α, GSK-3β, Beclin-1 | [25–29]             |
|                   | GLC4 cells      | 4 µM       | Cell growth inhibition                                        |                           | [30]                |
|                   | MDA-MB-231 cells| 80.0–640 µg/mL | Cell growth, invasion, metastasis, and adhesion inhibition; apoptosis and induction | c-Met kinase             | [31,32]             |
| Breast Cancer     | MCF-7 cells     | 19.4–46.1 µM | Cell growth inhibition via apoptotic induction                | p53, PTEN, p21; Cyclin B, caspase 3/7, ROS | [33–36]             |
| Cervical cancer   | HeLa cells      | 30–265 µg/mL | Cell growth inhibition via apoptotic induction                | ROS, caspase-3, E6, E7    | [37–39]             |
|                   | C33A cells      | 120 µM     | Cell growth inhibition via apoptotic induction                | ROS mediated             | [40]                |
| Colorectal cancer | HT-29 cells     | 100–300 µM  | Cell growth inhibition via apoptotic induction                | Bax, Bcl2, p53, caspases-3, -8, and-9, PARP, NF-κB, IKK-a and IKK-b, p38, and MK-2 | [27,41,42]          |
|                   | Caco-2 cells    | 711 µM     | Cell growth inhibition                                        | Superoxide               |                     |
|                   | LoVo cells      | 29 µM      | Cell growth inhibition via apoptotic induction and cell cycle arrest | ROS                      | [35]                |
|                   | HCT 116 cells   |            | Cell growth inhibition via apoptotic induction                | Caspase-3                | [43]                |
|                   | SW480 cells     | 600 mM     | Cell growth inhibition                                        | Cancer cell metabolism   | [37,44]             |
| Prostate cancer   | LNCaP cells     | 75.0 mM    | Cell growth inhibition via apoptotic induction                | -                         | [45]                |
|                   | PC-3 cells      | 91 µg/mL   | Cell growth inhibition                                        | -                         | [46]                |
| Pancreatic cancer | PANC-1 cells    | 26 µg/mL   | Cell growth inhibition via apoptotic induction                | Caspase-3/7              | [47]                |
| Liver cancer      | Hep G2 cells    | 10–200 µM  | Cell growth inhibition via apoptotic induction                | -                         | [36,47–51]          |
|                   | Murine HTC cells| 810 µM     | Cell growth inhibition                                        | -                         | [52]                |
| Neuroblastoma     | LAN-5 cells     | 25–100 µg/mL | Cell growth, invasion, and adhesion inhibition                | MYCN, Bax, Bcl2, TNFα   | [53]                |
|                   | Neuro-2a cells  | 24 µM      | Cell growth inhibition                                        | -                         | [54]                |
|                   | SK-N-SH cells   | 36 µM      | Cell growth inhibition                                        | -                         | [54]                |
| Melanoma          | SK-MEL-28       | 40 µM      | Cell growth inhibition via apoptotic induction                | GSH, ROS, MMP            | [55]                |
| Nasopharyngeal carcinoma | CNE-2 cells | 5–80 mg/L | Cell growth inhibition                                       | -                         | [56]                |
| Oral cancer       | CA9-22 cells    | 20–40 µM   | Autophagy induction                                          | NF-κB, ATG5/12 conjugation, LC3-II, Beclin-1, TNF-alpha | [57] |
|                   | KB cells        | 167 µg/mL  | Cell growth inhibition                                        | -                         | [58]                |
| Ovarian cancer    | OVCAR-3         | -          | Cell growth and VEGF inhibition                               | -                         | [59]                |
| Renal cancer      | 786-O          | 45.2 µM    | Cell growth inhibition                                        | -                         | [60]                |
| Gastric cancer    | SGC-7901        | 300 µM     | Cell growth inhibition via apoptotic induction                | p38 MAPK pathway         | [61]                |
Table 1. Cont.

| Cancer     | Cell Lines         | Doses       | Anticancer Mechanism                          | Molecular Targets | References |
|------------|--------------------|-------------|-----------------------------------------------|-------------------|------------|
| Glioma     | GL-15 cells        | 50–100 µM   | Cell growth inhibition via apoptotic induction | p-ERK1/2          | [62]       |
|            | CHME cells         | 15 µM       | Cell growth inhibition via apoptotic induction | p53, Bax, Bcl2,   | [54]       |
|            |                    |             |                                                | caspase-3/-9      |            |
|            | LN-229 cells       | 22 µM       | Cell growth inhibition                        |                   | [54]       |
|            | U-937 cells        | 9.6 µg/mL   | Cell growth inhibition                        |                   | [63]       |
|            | K562 cells         | 98.56 µg/mL | Cell growth inhibition via apoptotic induction |                   | [64,65]   |
| Leukemia   | ARH-77 cells       | 50–200 µM   | Cell growth inhibition via mitochondrial and  |                   |            |
|            |                    |             | lysosomal activities                          |                   |            |
|            | Leukocytes         | 1.50 µg/mL  | Cell growth inhibition                        |                   | [66]       |
|            | U937 cells         | 80 µg/mL    | Cell growth inhibition via apoptotic induction | GSK-3β            | [68]       |
|            | THP-1 cell-derived | 20–40 µM    | Autophagy induction                           |                   |            |
|            | macrophages        |             |                                                | NF-κB, ATG5/12    | [69]       |
|            |                    |             |                                                | conjugation, LC3-II, Beclin-1 |            |
|            | Leukemia stem      | 160 µg/mL   | Cell growth inhibition via apoptotic induction | GSK-3β            | [68]       |
|            | cells (CD123+/CD34+/CD38+) |        |                                                |                   |            |

Abbreviations: Atg5/12, autophagy related 5/12; Bax, Bcl-2 associated X protein; Bcl-2, B cell lymphoma 2; GSK-3β, glycogen synthase kinase 3 beta; LC3-II, light chain 3; PARP, poly (ADP ribose) polymerase; IKK, IκB kinase; MAPK, mitogen-activated protein kinase; MMP, mitochondrial membrane potential; N-myc proto-oncogene protein; NF-κB, nuclear factor kappa; ROS, reactive oxygen species; TNF-α, tumor necrosis factor alpha.

Apoptosis has been recognized as a crucial phenomenon for the maintenance of balanced cell growth [68]. However, altered cell signaling has been widely reported with a distressed apoptotic balance, leading to cancer proliferation and invasiveness. DDR (death receptor pathway) initiation has been linked with TRAIL (TNF-related apoptosis inducing ligand) and FasL (Fas ligand) binding with transmembrane receptors. This interaction ultimately results in caspase activation that subsequently promotes apoptosis pathway (intrinsic or extrinsic) activation. In addition, apoptosome formation (associated with caspase-9, cytochrome-C, and apoptotic protease-activating factor) triggers caspase-3 activation, leading to cell death. Several in vitro and in vivo studies have elaborated the chemopreventive potential of rutin against several cancer types (Table 2).

Table 2. In vivo antitumor efficacy of rutin and its mechanisms of action.

| Cancer Model | Cell Lines                     | Doses/Treatment | Anticancer Mechanism | Molecular Targets | References |
|--------------|--------------------------------|-----------------|----------------------|-------------------|------------|
| Cervical cancer | Human papillomavirus type 16 (HPV16)-transgenic mice | 24 weeks | Tumor growth inhibition | COX-2 | [70] |
|               | HeLa cells induced cervical cancer (i.p.) in female Wistar albino rats | 50 mg/kg and 70 mg/kg rutin for 45 days | Tumor growth inhibition | Modulation of hematological parameters and lipid peroxidation | [71] |
Table 2. Cont.

| Cancer Model | Cell Lines | Doses/Treatment | Anticancer Mechanism | Molecular Targets | References |
|--------------|------------|-----------------|----------------------|-------------------|------------|
| Leukemia     | Human leukemia HL-60 cells (s.c.) in both flanks of female BALB/c nu/nu mice | 120 mg/kg rutin once every four days | Tumor growth inhibition | - | [72] |
| Murine leukemia WEHI-3 cells (i.p.) in male BALB/c mice | 6 mg/kg and 12 mg/kg rutin for up to 3 weeks orally | Tumor growth inhibition | Modulation of whole blood cell surface markers | [73] |
| Human leukemic U-937 cells in male CD1 nu/nu nude mice and CD-1 mice | 5, 10, and 15 mg/kg for 9 days orally | Tumor growth inhibition | - | [74] |
| Breast cancer | MDA-MB-231/GFP cells induced breast cancer in female athymic Foxn1nu/Foxn1þ mice | 30.0 mg/kg rutin three times a week | Reduction in tumor growth | ROS, caspase-3, E6, E7 | [75] |
| Prostate cancer | PC-3-luc cells induced prostate cancer in male nude BALB/c mice | 100 mg/kg rutin daily for 4 weeks orally | Tumor growth inhibition | - | [76] |
| Lung cancer | B16Fi10 melanoma cells induced lung cancer in female Swiss albino mice | 0.2% w/v rutin for 21 days orally | Lung metastasis inhibition | Decrease in lung tumor nodules and invasion index | [77] |
| Colon cancer | SW480 colon cancer cells induced colon cancer in nu/nu mice | 1, 10, and 20 mg/kg rutin daily for 32 days i.p. | Tumor growth and angiogenesis inhibition | VEGF | [37] |
| Glioblastoma | U87 glioblastoma cells induced cancer in BALB/c athymic mice | 20 mg/kg rutin thrice a week for two weeks | Tumor growth inhibition via apoptotic induction | Decrease in autophagy and JNK expression | [78] |
| Liver cancer | DEN induced hepatocellular carcinoma in Wistar rats | 50 mg/kg rutin for 16 weeks orally | Inhibition of cell proliferation | Decrease in hepatocellular marker enzymes and tumor invasion | [79] |
| Aflatoxin B1 and N-nitrosodimethylamine induced hepatocellular carcinoma in Wistar rats | 1 and 10 mg/100 g rutin for 2 weeks orally | Protection from carcinogenesis by enzyme modulation | Decrease in PARP, DNA ligase, and polymerase beta | [80] |

Abbreviations: HPV, human papilloma virus; COX-2, cyclooxygenase-2; I.P., intraperitoneal; JNK, c-Jun N-terminal kinase; PARP, poly-ADP ribose polymerase; VEGF, vascular endothelial growth factor; ROS, reactive oxygen species.

3. Interaction of Rutin with Numerous Molecular Signaling Pathways

Cancer cells rapidly develop drug resistance against various therapeutic approaches which presents a major hindrance in the cancer management research of several pharmacologists and molecular biologists. This has further motivated researchers to develop drugs with limited cytotoxicity and high specificity. The following subsection explains rutin’s interactions with various molecular pathways.

3.1. Rutin’s Involvement in Modulation of Akt/PI3K/mTOR Signaling Pathway

Gene expression, translation, and transcription, and cell growth and proliferation are some of the major roles controlled by the Akt/PI3K/mTOR signaling pathway. Several reports have established the association between aberration in this signaling cascade and the progression of numerous carcinomas by triggering tumor growth, invasion, and metastasis [81,82]. In brief, PI3K is found downstream of tyrosine kinase growth receptors, due to which mutations in the Akt protein can inversely affect effector proteins and downstream signaling, thereby stimulating cancer cell growth and development [83]. Rutin has been found to employ its effect on the AkT/PI3K/mTOR pathway by modulating the expression...
of several key proteins, including AkT, PTEN, ERK, and others [84–86]. Later, it was further reported that rutin blocks the cross-talk between AkT and PI3K by blocking PI3K activity. Rutin treatment has also resulted in the attenuation of H2O2-induced oxidative damage and in apoptotic induction in Leydig cells via PI3K/Akt signaling pathways [87]. In addition, rutin prevents AkT phosphorylation by disturbing the PI3K-ATP binding domain and mTORC2 complex. Rutin mediated apoptotic induction via modulating Bcl-2, Bax, and caspase expression levels and also induced antioxidant activity by increasing antioxidants levels [88]. Rutin also deregulated the expression of numerous molecules, including GSK-3 (Glycogen synthase kinase-3). Further, rutin promoted TNF-α-induced apoptosis in A549 human lung cancer cells by modulating the expression level of the GSK-3β protein [89]. Rutin has also prevented GSK-3β phosphorylation by regulating PI3K expression and has displayed protection against γ-radiation or acrylamide-induced neurotoxicity through activation of the PI3K/AKT pathway by deregulating phosphorylation. Rutin prevents GSK-3β (AkT target) phosphorylation via PI3K inhibition [90]. Additionally, rutin has also been reported to increase the expression level of tumor suppressor proteins including FOXO3a, p21, KIP1, and CIP/WAF. The increased expression levels of these reported tumor suppressor proteins further promoted growth arrest in cancer cells. Rutin treatment prevented cisplatin (CP)-induced ovarian damage by regulating FOXO3a and PTEN phosphorylation and antioxidant activity in a mouse model [91]. Rutin has also been associated with the regulation of mTOR activity by modulating TSC2 expression [92]. Rutin-mediated protein kinase β activation promotes AMPK activation which results in TSC2 phosphorylation and inhibition of mTOR activity [93–95]. Altogether, these findings strongly suggest a reciprocal feedback mechanism which involves mTOR and AMPK in cancer cells and could be targeted for elucidating and developing potent therapeutics.

3.2. Rutin’s Involvement in Modulation of STAT Signaling

The STAT pathway is an evolutionarily conserved signaling pathway that is involved in the regulation of numerous cell processes including inflammation, immune cell development, migration, cell survival, apoptosis, cell homeostasis, and cell proliferation. Aberrant STAT signaling has been recognized as a hallmark of numerous cancers [96–99]. Rutin has been exploited for its potential role in inhibiting cancer cell growth and metastasis by inhibiting this signaling pathway. Rutin modulates this cellular pathway via the repression of SRC (kinases) phosphorylation, thereby inhibiting STAT 3 (signal transducers and activators of transcription 3) activation which further blocks the translocation of STAT to the nucleus [100,101]. STAT 3 has also been associated with the regulation of MMPs (membrane metalloproteases), VEGF, and TWIST1 which are crucial for cancer cell migration, proliferation, invasion, and angiogenesis. Rutin blocks the activation of TWIST1, MMPs, and VEGF via the inhibition of STAT3 phosphorylation [102,103]. Another study also reported that rutin treatment blocked UVB-induced STAT 3 activation via the inhibition of Tyr705 phosphorylation which explains the usefulness of rutin in preventing skin cancer [103]. Several studies have evidenced its potential anticancerous role in regulating the expression of key signaling components (STAT5, STAT3, and JAK2) in numerous carcinomas, thereby preventing cancer cell growth and differentiation (Figure 2).
activity [93–95]. Altogether, these findings strongly suggest a reciprocal feedback mechanism which involves mTOR and AMPK in cancer cells and could be targeted for elucidating and developing potent therapeutics.

3.2. Rutin’s Involvement in Modulation of STAT Signaling

The STAT pathway is an evolutionarily conserved signaling pathway that is involved in the regulation of numerous cell processes including inflammation, immune cell development, migration, cell survival, apoptosis, cell homeostasis, and cell proliferation. Aberrant STAT signaling has been recognized as a hallmark of numerous cancers [96–99]. Rutin has been exploited for its potential role in inhibiting cancer cell growth and metastasis by inhibiting this signaling pathway. Rutin modulates this cellular pathway via the repression of SRC (kinases) phosphorylation, thereby inhibiting STAT 3 (signal transducers and activators of transcription 3) activation which further blocks the translocation of STAT to the nucleus [100,101]. STAT 3 has also been associated with the regulation of MMPs (membrane metalloproteases), VEGF, and TWIST1 which are crucial for cancer cell migration, proliferation, invasion, and angiogenesis. Rutin blocks the activation of TWIST1, MMPs, and VEGF via the inhibition of STAT 3 phosphorylation [102,103]. Another study also reported that rutin treatment blocked UVB-induced STAT 3 activation via the inhibition of Tyr705 phosphorylation which explains the usefulness of rutin in preventing skin cancer [103]. Several studies have evidenced its potential anticancerous role in regulating the expression of key signaling components (STAT5, STAT3, and JAK2) in numerous carcinomas, thereby preventing cancer cell growth and differentiation (Figure 2).

Figure 2. Mechanism associated with the anticancer potential of rutin via the targeting of numerous molecular signaling pathways.

3.3. Rutin’s Involvement in Modulation of Wnt/β Catenin Signaling

Wnt/β catenin signaling contributes a crucial role in differentiation, organogenesis, cell migration, tissue homeostasis, and neuronal patterning. Modulated Wnt/β catenin signaling has been associated with the invasiveness and progression of several carcinomas [104–106]. Rutin has also been reported to induce variation in the expression level of downstream effectors of Wnt/β catenin signaling, including AXIN2, c-MYC, and cyclin D1 [107]. Further research studies have also revealed that rutin prevents the stabilization and accumulation of β-catenin in the cytoplasm and also blocks its translocation in the nucleus via the repression of the PI3K/Akt/mTOR pathway [68]. From these research findings, it can be concluded that rutin can be considered a potent therapeutic option for the management of numerous carcinomas.

3.4. Rutin’s Involvement in Modulation of MAPK Signaling

The MAPK family consists of three major classes of activated kinases including ERK/MAPK, p38 kinase, and c-JUN/SAPK that play a crucial role in cell proliferation, invasion, homeostasis, and differentiation and cell death. Overexpression of numerous ERK protein family members has been exclusively reported in the modulation of the MAPK-ERK pathway [108]. In numerous carcinomas, ERK signaling is activated via mutation in either the tyrosine kinase receptor or the kinase genes RAS and RAF. Rutin has presented significant antiproliferative effects in numerous cancer cell lines by modulating the expression of DR4/DR5, Akt, ERK, and NF-kB. Rutin exposure has promoted TRAIL-mediated apoptosis in numerous carcinomas such as lung cancer [109–112]. Additionally, rutin has been utilized to suppress the growth, invasion, proliferation, and metastasis of several melanoma cells. Specifically, in A375 and C8161 melanoma cell lines, rutin administration promoted growth arrest via the downregulation of p-Akt, p-ERK1/2, and p-mTOR. Rutin treatment has significantly downregulated the expression level of p-ERK1/2 (phospho-
extracellular signal-regulated kinase 1/2) in glioma cells [113]. Other studies have also reported that rutin treatment leads to a significant reduction in the expression level of p38 MAPK in lung cancer (A549) cells. Moreover, rutin has strong potential to activate p38 MAPK in colon cancer cells (HT-29), either alone or in combination with silibinin [112]. Conclusively, these experimental findings shed enormous light on the fact that rutin can induce apoptosis via the suppression of the aberrant MAPK/ERK signaling pathway.

3.5. Rutin’s Targeting of Apoptotic Pathways and Autophagy Signaling Molecules

Rutin has presented potent efficacy in apoptosis induction in cancer cells. Rutin elicited the intrinsic apoptosis pathway in neuroblastoma cells as shown by the reduced Bcl2 protein and Bcl2/Bax ratio [114]. Likewise, in HCT (colon cancer) cells, rutin treatment induced caspase-3 activation [43]. Furthermore, rutin has been shown to activate both the intrinsic and extrinsic apoptotic pathways in colon cancer cells (HT-29) by upregulating caspasases and Bax, and downregulating Bcl-2 levels [110]. This evidence strongly supports the apoptosis-inducing potential of rutin in cancer cells via the induction of both the intrinsic (mitochondria-mediated) and extrinsic (death receptor-mediated) apoptotic pathways.

Rutin exposure to cancer cells can also induce apoptosis via p53 activation [33,54,110]. Rutin treatment can also lead to an increase in the PTEN (tumor suppressor) mRNA expression level, resulting in apoptosis-mediated growth arrest in breast cancer cells [33,115]. ER targeting has also emerged as one of the promising approaches for cancer prevention and treatment [116]. A study conducted by Nasri Nasrabad [44] et al. identified altered molecular signaling pathways and differentially expressed genes in rutin-treated colorectal cancer cell lines. ROS (reactive oxygen species), generated during metabolism, are also associated with numerous physiological functions. The balance between ROS production and their elimination via the antioxidant defense system is properly regulated in normal cells, whereas ROS homeostasis is dysregulated in cancerous cells, leading to elevated ROS levels. ROS have also been explored as a potent therapeutic tool for cancer management because elevated ROS generation could trigger apoptosis in cancer cells [117]. Rutin treatment has induced significant apoptosis by activating ROS-dependent apoptosis pathways in numerous cancer cells including MCF-7, HepG2, LoVo, HeLa, and C33A cancer cells [35,40].

Deregulated autophagy (catabolic process) has also been crucially associated with several cancer types. Signaling molecules such as ATGs (autophagy-related genes), which are mainly involved in autophagy, include ATG6, ATG5, ATG12, and LC3 (microtubule associated protein 1 A/1B-light chain 3). Several studies have projected that autophagy greatly contributes to the inhibition of cancer cell growth. Further, rutin treatment has induced autophagy in several cancer cells such as A549, THP1, and CA9-22. Rutin treatment has also resulted in an enhanced expression level of Beclin1 and has triggered the formation of the ATG5/12 complex. LC3-II (hallmark of autophagy) activation was also observed in rutin-treated cancer cells, thereby leading to autophagy-mediated cancer cell death [57].

4. Rutin and miRNA (microRNAs) Interplay: Potent Approach in Cancer Management

MicroRNAs (small molecules with a size range of 10–25 bp) have received profound attention in cancer management therapies because of their potent involvement in gene transcription and translation [118]. Several studies have reported that dysregulated microRNAs (miRNA) make major contributions to cancer progression and thus they can be considered an effective target in cancer therapies. This section focuses on revealing the interplay between rutin and miRNAs, and how rutin treatment modulates the expression of various tumor suppressor and oncogenic miRNAs in cancer. Recently, it has come to light that rutin restrains the proliferation of mouse breast cancer cells via the regulation of the miR-129-1-3p/Ca2+ signaling pathway, thereby revealing its potential as a strong drug candidate for the inhibition of tumor growth. Rutin, in combination with various miRNA mimics and inhibitors, has aided in cell apoptosis or growth arrest in numerous cancer cells [119,120]. Rutin has also shown significant inhibition of myocardial oxidative insults
by adjusting ROS (reactive oxygen species) levels. This further explains the protective effect of rutin on THP cardiotoxicity via the regulation of JunD gene expression by miR-125b-1-3p, which reveals the protective efficacy of rutin on THP-induced cardiotoxicity and provides a strong base for the utilization of rutin as a potent protective candidate against THP cardiotoxicity. Thus, it may be concluded that rutin could modulate several cancer-relevant miRNAs such as miR-155, let-7, miR-146a, and miR-21, thereby potentially inhibiting cancer development and progression [121–124]. However, more experimental research is still needed to study how rutin modulates this complex and broad range of both tumor suppressor and oncogenic miRNAs. Therefore, future studies should emphasize elucidating direct miRNA targets of rutin as well the process needed in transforming these approaches for developing novel therapeutic interventions for numerous cancers.

5. Conclusions

In several natural products, rutin contributes to potent biological activities including anticancerous effects. Rutin has been shown to utilize numerous mechanisms to obstruct cancer initiation and progression by modulating several deregulated signaling pathways involved in apoptosis, inflammation, angiogenesis, and autophagy. Specifically, the anti-cancer potential of rutin has been linked to the regulation of multiple signaling pathways, including NF-κB, PI3K/Akt/mTOR, Nrf2, ERK, JNK, and p38 MAPK. This bioactive plant-derived compound significantly interferes with numerous intracellular signaling molecules, such as TNF-α, Bax, ILs, Beclin, VEGF, Bcl-2, and caspases. Extensive in vitro and in vivo studies have clearly revealed therapeutic targets of rutin such as Bcl-2, p53, caspases, Bax, NF-κB, TNF-α, Akt, and GSH. Rutin has shown tremendous anticancer potential against a range of cancer cell lines including glioblastoma, breast cancer, lung adenocarcinoma, prostate cancer, cervical cancer, gastric cancer, leukemia, hepatocellular carcinoma, and colon cancer cell lines. Despite several preclinical mechanistic reports on the anticancer efficacies of rutin, the lack of well-framed clinical trials on the safety and therapeutic potential of rutin increases the need for more potent clinical studies. Further, more elaborative studies (concerning engineering methods) are also needed to achieve a better targeted drug delivery approach for cancer management. Altogether, researchers should focus their study towards elucidating the novel molecular targets of rutin and the associated mechanism by which rutin mediates cancer cell growth arrest via molecular cross-talks and signaling cascades. Overall, rutin has enormous medicinal potential and could be employed as a potent therapeutic agent through extensive investigation into its potential to modulate numerous cell signaling pathways and apoptosis pathways involved in cancer progression.

Author Contributions: Conceptualization, P.P. and F.K.; methodology, P.P. and F.K.; resources, P.P. and F.K.; writing—original draft preparation, P.P. and F.K.; writing—review and editing, P.P. and F.K.; visualization, P.P. and F.K.; supervision, P.P. and F.K.; project administration, P.P., F.K., H.A.Q. and M.O.; writing—review and editing, H.A.Q. and M.O.; funding acquisition, H.A.Q. and M.O. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Dean of Scientific Research (DSR), King Abdulaziz University, Jeddah (IFPRP:332-188-1442), with the name of the Institutional Funding Program.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data sharing not applicable.

Acknowledgments: We are highly grateful to the Dean of Scientific Research (DSR), King Abdulaziz University, Jeddah, for providing the grant (IFPRP:332-188-1442) with the name of the Institutional Funding Program.

Conflicts of Interest: The authors declare that they have no conflict of interest.
References

1. The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. *Nature* 2020, 578, 82–93. [CrossRef]

2. Chen, Y.; Henson, E.S.; Xiao, W.; Huang, D.; McMillan-Ward, E.M.; Israels, S.J.; Gibson, S.B. Tyrosine kinase receptor EGFR regulates the switch in cancer cells between cell survival and cell death induced by autophagy in hypoxia. *Autophagy* 2016, 12, 1029–1046. [CrossRef]

3. Fakhri, S.; Abbasszadeh, F.; Jorjani, M.; Pourgholami, M.H. The effects of anticancer medicinal herbs on vascular endothelial growth factor based on pharmacological aspects: A review study. *Nutr. Cancer* 2019, 73, 1–15. [CrossRef]

4. Ohlwang’i, D.O.; Kimwele, C.N.; Oduma, J.A.; Gathumbi, P.K.; Mbaria, J.M.; Kiama, S.G. Medicinal plants used in treatment and management of cancer in Kakamega County, Kenya. *J. Ethnopharmacol.* 2014, 151, 1040–1055. [CrossRef]

5. Slattery, M.L.; Herrick, J.S.; Mullany, L.E.; Samowitz, W.S.; Sevens, J.R.; Sakoda, L.; Wolff, R.K. The co-regulatory networks of tumor suppressor genes, oncogenes, and miRNAs in colorectal cancer. *Genes Chromosom Cancer* 2017, 56, 769–787. [CrossRef] [PubMed]

6. Croce, C.M.; Reed, J.C. Finally, an apoptosis-targeting therapeutic for cancer. *Cancer Res.* 2016, 76, 5914–5920. [CrossRef] [PubMed]

7. Monkkonen, T.; Debnath, J. Inflammatory signaling cascades and autophagy in cancer. *Autophagy* 2018, 14, 190–198. [CrossRef] [PubMed]

8. Telkoparan-Akilillar, P.; Panieri, E.; Cevik, D.; Suzen, S.; Saso, L. Therapeutic targeting of the NRF2 signaling pathway in cancer. *Molecules* 2021, 26, 1417. [CrossRef]

9. Mahato, M.; Patra, S.; Gogoij, M. Herbal Nanocarriers for cancer therapy. In *Nanopharmaceuticals: Principles and Applications*; Springer: Cham, Switzerland, 2021; Volume 2, pp. 41–75.

10. Najafi, M.; Mortezaei, K.; Rahimifard, M.; Farhood, B.; Haghi-Aminjan, H. The role of curcumin/curcuminoids during gastric cancer chemotherapy: A systematic review of non-clinical study. *Life Sci.* 2020, 257, 118051. [CrossRef]

11. Bishayeey, A.; Sethi, G. Bioactive natural products in cancer prevention and therapy: Progress and promise. *Semin. Cancer Biol.* 2016, 40–41, 1–3. [CrossRef]

12. Bordoloi, D.; Roy, N.K.; Monisha, J.; Padmavathi, G.; Kunnunakkara, A. Multi-targeted agents in cancer cell chemosensitization: What we learnt from curcumin thus far. *Recent Pat. Anticancer Drug Discov.* 2016, 11, 67–97. [CrossRef]

13. Fakhri, S.; Khodamorady, M.; Naseri, M.; Farzaei, M.H.; Khan, H. The ameliorating effects of anthocyanins on the cross-linked signaling pathways of cancer dysregulated metabolism. *Pharmcol. Res. 2020, 159, 104895. [CrossRef] [PubMed]

14. Brarui, C.; Zanoaga, O.; Zinta, A.-A.; Tigu, A.B.; Kilpatrick, K.L.; Bishayee, A.; Nabavi, S.M.; Berindan-Neagoe, I. Natural compounds modulate the crosstalk between apoptosis-and autophagy-regulated signaling pathways: Controlling the uncontrolled expansion of tumor cells. In *Seminars in Cancer Biology*; Academic Press: Cambridge, MA, USA, 2020. [CrossRef]

15. Prasad, R.; Prasad, S.B. A review on the chemistry and biological properties of Rutin, a promising nutraceutical agent. *Asian J. Pharm. Pharmacol.* 2019, 5, 1–20. [CrossRef]

16. Yang, C.-Y.; Hsiu, S.-L.; Wen, K.-C.; Lin, S.-P.; Tsai, S.-Y.; Hou, Y.-C.; Chao, P.-D. Bioavailability and metabolic pharmacokinetics of rutin and quercetin in rats. *J. Food Drug Anal.* 2016, 24, 40–41, 1–20. [CrossRef]

17. Gautam, R.; Singh, M.; Gautam, S.; Rawat, J.K.; Saraf, S.A.; Kaithwas, G. Rutin attenuates intestinal toxicity induced by Methotrexate linked with anti-oxidative and anti-inflammatory effects. *BMC Complement. Altern. Med.* 2016, 16, 99. [CrossRef] [PubMed]

18. Satari, A.; Ghasemi, S.; Habtemariam, S.; Asgharian, S.; Lorigoon, Z. Rutin: A Flavonoid as an Effective Sensitizer for Anticancer Therapy; Insights into Multifaceted Mechanisms and Applicability for Combination Therapy. *Evid.-Based Complement. Altern. Ther.* 2021, 2021, 9913179. [CrossRef]

19. Zheng, Y.; Zhao, Z.; Fan, L.; Meng, S.; Song, C.; Qiu, L.; Xu, P.; Chen, J. Dietary supplementation with rutin has pro-/anti-inflammatory effects in the liver of juvenile GIFT tilapia, Oreochromis niloticus. *Fish Shellfish. Immunol.* 2017, 64, 49–55. [CrossRef]

20. Perk, A.A.; Shatynska-Mytsyk, I.; Gerccek, Y.C.; Boztas, K.; Yazgan, M.; Favyaz, S.; Farooqi, A.A. Rutin mediated targeting of signaling machinery in cancer cells. *Cancer Cell Int.* 2014, 14, 1–5. [CrossRef]

21. Paudel, K.R.; Wadhwa, R.; Tew, X.N.; Lau, N.J.X.; Madheswaran, T.; Panneerselvam, J.; Zeeshan, F.; Kumar, P.; Gupta, G.; Anand, K.; et al. Rutin loaded liquid crystalline nanoparticles inhibit non-small cell lung cancer proliferation and migration in vitro. *Life Sci.* 2021, 276, 119436. [CrossRef] [PubMed]

22. Chang, C.; Zhang, L.; Miao, Y.; Fang, B.; Yang, Z. Anticancer and apoptotic-inducing effects of rutin-chitosan nanoconjugates in triple negative breast cancer cells. *J. Clust. Sci.* 2021, 32, 331–340. [CrossRef]

23. Hoai, T.T.; Yen, P.T.; Dao, T.T.B.; Long, L.H.; Anh, D.X.; Minh, L.H.; Anh, B.Q.; Thuong, N. T. Evaluation of the Cytotoxic Effect of Rutin Prenanoemulsion in Lung and Colon Cancer Cell Lines. *J. Nanomater.* 2020, 2020, 1–11. [CrossRef]

24. Goitia, H.; Quispe, P.; Naso, L.G.; Martinez, V.R.; Rey, M.; Rizzi, A.C.; Ferrer, E.G.; Williams, P.A. Interactions of rutin with the oxidovanadium (IV) cation. Anticancer improvement effects of glycosylated flavonoids. *New J. Chem.* 2019, 43, 17636–17646. [CrossRef]

25. Fu, Y.; Sui, B.; Xiang, L.; Yan, X.; Wu, D.; Shi, S.; Hu, X. Emerging understanding of apoptosis in mediating mesenchymal stem cell therapy. *Cell Death Dis.* 2021, 12, 1–12. [CrossRef]
26. Li, X.H.; Liu, Z.Y.; Gu, Y.; Lv, Z.; Chen, Y.; Gao, H.C. Expression of NF-kappaB and p38 under intervention of rutin in lung cancer therapy. *Biomed. Res.* 2017, 28, 2344–2347.

27. ben Sghaier, M.; Pagano, A.; Mousslim, M.; Ammari, Y.; Kovacic, H.; Luis, J. Rutin inhibits proliferation, attenuates superoxide production and decreases adhesion and migration of human cancerous cells. *Biomed. Pharmacother.* 2016, 84, 1972–1978. [CrossRef]

28. Vasiljević, B.; Kněžević-Vukčević, J.; Mitić-Čulafić, D.; Orčić, D.; Francišković, M.; Srdić-Rajic, T.; Jovanović, M.; Nikolić, B. Chemical characterization, antioxidant, genotoxic and in vitro cytotoxic activity assessment of *juniperus communis* var. saxatilis. *Food Chem. Toxicol.* 2018, 112, 118–125. [CrossRef]

29. Zhang, Z.; Shi, J.; Nice, E.C.; Huang, C.; Shi, Z. The Multifaceted Role of Flavonoids in Cancer Therapy: Leveraging Autophagy with a Double-Edged Sword. *Antioxidants* 2021, 10, 1138. [CrossRef]

30. Choiprasert, W.; Dechsupa, N.; Kothan, S.; Garrigos, M.; Mankhetkorn, S. Quercetin, quercetrin except rutin potentially increased pirarubicin cytotoxicity by non-competitively inhibiting the P-glycoprotein-and MRP1 function in living KS62/adr and GLC4/adr cells. *Am. J. Pharm. Toxicol.* 2010, 5, 24–33. [CrossRef]

31. Ghasezmadeh, A.; Jaafar, H.Z.; Rahmat, A.; Devarajan, T. Evaluation of bioactive compounds, pharmaceutical quality, and anticancer activity of curry leaf (*Murraya koenigii* L.). *Evid.-Based Complement. Altern. Med.* 2014, 2014, 873803. [CrossRef]

32. Makrane, H.; El Messaoudi, M.; Melhaoui, A.; El Mzibri, M.; Benbacer, L.; Aziz, M. Cytotoxicity of the Aqueous Extract and Organic Fractions from *Origanum majorana* on Human Breast Cell Line MDA-MB-231 and Human Colon Cell Line HT-29. *Adv. Pharmacol. Sci.* 2018, 2018, 3297193. [CrossRef]

33. Hasani, N.A.H.; Amin, I.M.; Kamaludin, R.; Rosdyd, N.M.M.N.M.; Ibahim, M.J.; Kadir, S.H.S.A. P53 and cyclin B1 mediate apoptosis of apigenin and rutin in EKap breast cancer MCF-7 cells. *J. Teknol.* 2018, 80, 133–140.

34. Noman, O.M.; Nasr, F.A.; Alqahtani, A.S.; Al-zharani, M.; Cordero, M.A.W.; Alotaibi, A.A.; Asmatanzeem, B.; Saud, A.; Daoud, A. Comparative study of antioxidant and anticancer activities and HPTLC quantification of rutin in white radish (*Raphanus sativus* L.) leaves and root extracts grown in Saudi Arabia. *Open Chem.* 2021, 19, 408–416. [CrossRef]

35. Yang, S.; Zhang, H.; Yang, X.; Zhao, H.; Zhu, Y. Evaluation of antiproliferative activities of rutin on human colon cancer LoVo cells and breast cancer MCF-7 cells. *Anal. Quant. Cytopathol. Histopathol.* 2017, 39, 99–107.

36. Iriri, M.; Kubina, R.; Cochis, A.; Sorrentino, R.; Varoni, E.M.; Kabala-Dzik, A.; Azzimonti, B.; Dziedzic, A.; Rimondini, L.; Wojtyczka, R.D. Rutin, a Quercetin Glycoside, Restores Chemosensitivity in Human Breast Cancer Cells. *Phytother. Res.* 2013, 27, 1529–1538. [CrossRef]

37. Alonso-Castro, A.J.; Domínguez, F.; García-Carranca, A. Rutin exerts antitumor effects on nude mice bearing SW480 tumor. *Arch. Med. Res.* 2013, 44, 346–351. [CrossRef]

38. Deepika, M.S.; Thangam, R.; Sheena, T.S.; Sasirekha, R.; Sivabubramanian, S.; Babu, M.D.; Jeganathan, K.; Thirumurugan, R. A novel rutin-fucoidan complex based phytotherapy for cervical cancer through achieving enhanced bioavailability and cancer cell apoptosis. *Biomed. Pharmacother.* 2019, 109, 1181–1195. [CrossRef] [PubMed]

39. Pandey, P.; Khan, F.; Maurya, P. Targeting Jab1 using hesperidin (dietary phytocompound) for inducing apoptosis in HeLa cervical cancer cells. *J. Food Biochem.* 2021, 45, e13800. [CrossRef] [PubMed]

40. Khan, F.; Pandey, P.; Upadhyay, T.K.; Jafri, A.; Jha, N.K.; Mishra, R.; Singh, V. Anti-cancerous effect of rutin against HPVC33A cervical cancer cells via G0/G1 cell cycle arrest and apoptotic induction. *Endocr. Metab. Immune Disord. Drug Targets* 2020, 20, 409–418. [CrossRef] [PubMed]

41. Guo, T.E.; Chung, H.S. Hyperoside and rutin of Nelumbo nucifera induce mitochondrial apoptosis through a caspase-dependent mechanism in HT-29 human colon cancer cells. *Oncol. Lett.* 2016, 11, 2463–2470. [CrossRef] [PubMed]

42. Nafees, S.; Mehdi, S.H.; Zafaryab, M.; Zeya, B.; Sarwar, T.; Rizvi, M.A. Synergistic interaction of rutin and silibinin on human cervical cancer cells. *Arch. Med. Res.* 2016, 47, 226–234. [CrossRef]

43. Jayameena, P.; Sivakumari, K.; Ashok, K.; Rajesh, S. Rutin: A potential anticancer drug against human colon cancer (HCT116) cells. *Int. J. Biol. Pharm. Allied Sci.* 2018, 7, 1731–1745.

44. Nasr Nasrabadi, P.; Zareian, S.Z.; Nayeri, R.; Salmanipour, S.; Parsafar, E.; Gharib, E.H.A.; Zali, M.R. A detailed image of rutin in human breast cancer therapy. *Biomed. Res.* 2017, 28, 2344–2347.

45. Romero, I.; Paez, A.; Ferrueto, A.; Lujan, M.; Berenguer, A. Polyphenols in red wine induce the proliferation and induce apoptosis of LNCaP cells. *BJU Int.* 2002, 89, 950–954. [CrossRef]

46. Ding, Y.; Ren, K.; Dong, H.; Song, F.; Chen, J.; Guo, Y.; Liu, Y.; Tao, W.; Zhang, Y. Flavonoids from persimmon (*Diospyros kaki* L.) leaves inhibit proliferation and induce apoptosis in PC-3 cells by activation of oxidative stress and mitochondrial apoptosis. *Chem. Biol. Interact.* 2017, 275, 210–217. [CrossRef] [PubMed]

47. Saleh, A.; El Fayouni, H.M.; Youns, M.; Barakat, W. Rutin and orlistat produce antitumor effects via antioxidant and apoptotic actions. *Naunyn Schmiedeb. Arch. Pharmacol.* 2019, 392, 165–175. [CrossRef] [PubMed]

48. Shen, Q.; Chen, M.A.; Chen, G. Effect of rutin on proliferation of HepG2 cells. *Acta Acad. Med. Mil. Tertiae* 2006, 28, 1885–1887.

49. Karakurt, S. Modulatory effects of rutin on the expression of cytochrome P450s and antioxidant enzymes in human hepatoma cells. *Acta Pharm.* 2016, 66, 491–502. [CrossRef] [PubMed]

50. Li, Y.; Duan, S.; Jia, H.; Bai, C.; Zhang, L.; Wang, Z. Flavonoids from tartary buckwheat induce G2/M cell cycle arrest and apoptosis in human hepatoma HepG2 cells. *Acta Biochim. Biophys. Sin.* 2014, 46, 460–470. [CrossRef] [PubMed]
51. Alia, M.; Mateos, R.; Ramos, S.; Lecumberri, E.; Bravo, L.; Goya, L. Influence of quercetin and rutin on growth and antioxidant defense system of a human hepatoma cell line (HepG2). *Eur. J. Nutr.* 2006, 45, 19–28. [CrossRef] [PubMed]

52. Marcarini, J.C.; Tsuoy, M.S.F.; Luiz, R.C.; Ribeiro, L.R.; Hoffmann-Campo, C.B.; Mantovani, M.S. Investigation of cytotoxic, apoptosis-inducing, genotoxic and protective effects of the flavonoid rutin in HTC hepatic cells. *Exp. Toxicol. Pathol.* 2011, 63, 459–465. [CrossRef]

53. Chen, H.; Miao, Q.; Geng, M.; Liu, J.; Hu, Y.; Tian, L.; Pan, J.; Yang, Y. Anti-tumor effect of rutin on human neuroblastoma cell lines through inducing G2/M cell cycle arrest and promoting apoptosis. *Sci. World J.* 2013, 2013, 269165. [CrossRef]

54. Yan, X.; Hao, Y.; Chen, S.; Jia, G.; Guo, Y.; Zhang, G.; Wang, C.; Cheng, R.; Hu, T.; Zhang, X.; et al. Rutin induces apoptosis via P53 up-regulation in human glioma CHME cells. *Transl. Cancer Res.* 2019, 8, 2005–2013. [CrossRef]

55. Vad, N.; Naik, B.; Moridani, M. Abstract #678: Biochemical Mechanism of Rutin Toxicity in SK-MEL-28 Melanoma Cells: A Tyrosinase Bioactivation Prodrug Approach; American Association for Cancer Research (AACR): Denver, CO, USA; Philadelphia, PA, USA, 2009.

56. Zhan, P.; Peng, X.S.; Xu, X.M.; Zhou, Y.F.; Zhang, X.P.; He, R.; Zhou, G.J. The anti-cancer study on combining paeonol and rutin. *Chin. Arch. Trad Chin. Med.* 2010, 28, 1710–1712.

57. Park, M.H.; Kim, S.; Song, Y.R.; Kim, S.; Kim, H.J.; Na, H.S.; Chung, J. Rutin induces autophagy in cancer cells. *Int. J. Oral Biol.* 2016, 41, 45–51. [CrossRef]

58. Luo, H.; Jiang, B.H.; King, S.M.; Chen, Y.C. Inhibition of cell growth and VEGF expression in ovarian cancer cells by flavonoids. *Nutr. Cancer* 2008, 60, 800–809. [CrossRef]

59. Nakajima, M.; Morikawa, M.; Nakamura, T.; Nakamura, S.; Endo, Y.; Kato, S.; Kato, M.; Nishimura, Y.; Matsui, T.; et al. Inhibitory effect of rutin on cell growth in human colon cancer cell lines through inducing G2/M cell cycle arrest and promoting apoptosis. *Toxics* 2019, 7, 46. [CrossRef] [PubMed]

60. Caparica, R.; Julio, A.; Araujo, M.E.M.; Baby, A.R.; Fonte, P.; Costa, J.G.; Santos de Almeida, T. Anticancer activity of rutin and its combination with ionic liquids on renal cells. *Biomolecules* 2020, 10, 233. [CrossRef]

61. Li, Q.; Ren, L.; Zhang, Y.; Gu, Z.; Tan, Q.; Zhang, T.; Qin, M.; Chen, S. P38 signal transduction pathway has more cofactors on apoptosis of SGC-7901 gastric cancer cells induced by combination of rutin and oxaliplatin. *Biomed. Res. Int.* 2019, 2019, 6407210. [CrossRef] [PubMed]

62. Santos, U.P.; Campos, J.F.; Torquato, H.F.V.; Paredes-Gamero, E.J.; Carollo, C.A.; Estevinho, L.M.; Souza, K.P.; Dos Santos, E.L. Antioxidant, antimicrobial and cytotoxic properties as well as the phenolic content of the extract from *Hancornia speciosa* Gomes. *PLoS ONE* 2016, 11, e0167531.

63. Beckmann, L.; Rolling, C.C.; Voigtländer, M.; Mäder, J.; Klingler, F.; Schulenkorf, A.; Lehr, C.; Bokemeyer, C.; Ruf, W.; Langer, F. Apoptotic induction in K562 human leukemic cells. *Apoptosis* 2010, 15, 1039–1049. [CrossRef] [PubMed]

64. Wangchauy, C.; Chanprasert, S. Effects of *H. littoralis* leaf extract on cell proliferation and cell cycle progression in human osteosarcoma cells. *Toxins* 2012, 4, 1290–1299. [CrossRef] [PubMed]

65. Kikuchi, H.; Yuan, B.; Hu, X.; Okazaki, M. Chemopreventive and anticaner activity of flavonoids and its combination with ionic liquids on renal cells. *Biomolecules* 2020, 10, 233. [CrossRef]

66. Marcarini, J.C.; Tsuboy, M.S.F.; Luiz, R.C.; Ribeiro, L.R.; Hoffmann-Campo, C.B.; Mantovani, M.S. Investigation of cytotoxic, apoptosis-inducing, genotoxic and protective effects of the flavonoid rutin in HTC hepatic cells. *Exp. Toxicol. Pathol.* 2011, 63, 459–465. [CrossRef]

67. Alia, M.; Mateos, R.; Ramos, S.; Lecumberri, E.; Bravo, L.; Goya, L. Influence of quercetin and rutin on growth and antioxidant defense system of a human hepatoma cell line (HepG2). *Eur. J. Nutr.* 2006, 45, 19–28. [CrossRef] [PubMed]

68. Bourogaa, E.; Bertrand, J.; Despeaux, M.; Jarraya, R.; Fabre, N.; Payrastre, L.; Demur, C.; Fournier, J.J.; Damak, M.; Feki, A.E. Apoptotic induction in K562 human leukemic cells. *Apoptosis* 2010, 15, 1039–1049. [CrossRef] [PubMed]

69. Pinzaru, I.; Chioibas, R.; Marcovici, I.; Coricovac, D.; Susan, R.; Predut, D.; Georgescu, D.; Dehelean, C. Rutin Exerts Cytotoxic Effects on Human Leukemia Cells. *Toxins* 2021, 13, 3941. [CrossRef]

70. Moutinho, M.S.S.; Aragão, S.; Ribeiro, L.R.; Hoffmann-Campo, C.B.; Mantovani, M.S. Investigation of cytotoxic, apoptosis-inducing, genotoxic and protective effects of the flavonoid rutin in HTC hepatic cells. *Exp. Toxicol. Pathol.* 2011, 63, 459–465. [CrossRef]

71. Vad, N.; Naik, B.; Moridani, M. Abstract #678: Biochemical Mechanism of Rutin Toxicity in SK-MEL-28 Melanoma Cells: A Tyrosinase Bioactivation Prodrug Approach; American Association for Cancer Research (AACR): Denver, CO, USA; Philadelphia, PA, USA, 2009.

72. Santos, U.P.; Campos, J.F.; Torquato, H.F.V.; Paredes-Gamero, E.J.; Carollo, C.A.; Estevinho, L.M.; Souza, K.P.; Dos Santos, E.L. Antioxidant, antimicrobial and cytotoxic properties as well as the phenolic content of the extract from *Hancornia speciosa* Gomes. *PLoS ONE* 2016, 11, e0167531.

73. Moutinho, M.S.S.; Aragão, S.; Ribeiro, L.R.; Hoffmann-Campo, C.B.; Mantovani, M.S. Investigation of cytotoxic, apoptosis-inducing, genotoxic and protective effects of the flavonoid rutin in HTC hepatic cells. *Exp. Toxicol. Pathol.* 2011, 63, 459–465. [CrossRef]

74. Marcarini, J.C.; Tsuboy, M.S.F.; Luiz, R.C.; Ribeiro, L.R.; Hoffmann-Campo, C.B.; Mantovani, M.S. Investigation of cytotoxic, apoptosis-inducing, genotoxic and protective effects of the flavonoid rutin in HTC hepatic cells. *Exp. Toxicol. Pathol.* 2011, 63, 459–465. [CrossRef] [PubMed]

75. Alia, M.; Mateos, R.; Ramos, S.; Lecumberri, E.; Bravo, L.; Goya, L. Influence of quercetin and rutin on growth and antioxidant defense system of a human hepatoma cell line (HepG2). *Eur. J. Nutr.* 2006, 45, 19–28. [CrossRef] [PubMed]
76. Yang, C.; Gundala, S.R.; Mukkavilli, R.; Vangala, S.; Reid, M.D.; Aneja, R. Synergistic interactions among flavonoids and acetogenins in Graviola (Annona muricata) leaves confer protection against prostate cancer. *Carcinogenesis* 2015, 36, 656–665. [CrossRef] [PubMed]

77. Martínez Conesa, C.; Vicente Ortega, V.; Yáñez Gascón, M.J.; Alcaraz Baños, M.; Cantera Jordana, M.; Benavente-García, O.; Castillo, J. Treatment of metastatic melanoma B16F10 by the flavonoids tangeretin, rutin, and diosmine. *J. Agric. Food Chem.* 2005, 53, 6791–6797. [CrossRef] [PubMed]

78. Zhang, P.; Sun, S.; Li, N.; Ho, A.S.W.; Kiang, K.M.Y.; Zhang, X.; Cheng, Y.S.; Poon, M.W.; Lee, D.; Pu, J.K.S.; et al. Rutin increases the cytotoxicity of temozolomide in glioblastoma via autophagy inhibition. *J. Neurooncol.* 2017, 132, 393–400. [CrossRef] [PubMed]

79. Chandra, Y.P.; Viswanathswamy, A.H.M. Chemo preventive effect of rutin against N-nitrosodiethylamine-induced and phenobarbital-promoted hepatocellular carcinoma in Wistar rats. *Indian J. Pharm. Educ. Res.* 2018, 52, 78–86. [CrossRef]

80. Webster, R.P.; Gawde, M.D.; Bhattacharya, R.K. Protective effect of rutin, a flavonol glycoside, on the carcinogen-induced DNA damage and repair enzymes in rats. *Cancer Lett.* 1996, 109, 185–191. [CrossRef]

81. Park, S.; Chapuis, N.; Tamburini, J.; Bardet, V.; Cornillet-Lefebvre, P.; Willems, L.; Green, A.; Mayeux, P.; Lacombe, C.; Bouscary, D. Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. *Haematologica* 2010, 95, 819–828. [CrossRef]

82. Sharma, V.R.; Gupta, G.K.; Sharma, A.K.; Batra, N.; Sharma, D.K.; Joshi, A.; Sharma, A.K. PI3K/Akt/mTOR Intracellular Pathway and Breast Cancer: Factors, Mechanism and Regulation. *Curr. Pharm. Des.* 2017, 23, 1633–1638. [CrossRef]

83. Fattahi, S.; Amjadi-Mohef, F.; Tabarinpour, R.; Ashrafi, G.H.; Akhvan-Niaiki, H. PI3K/AKT/mTOR signaling in gastric cancer: Epigeneics and beyond. *Life Sci.* 2020, 262, 118513. [CrossRef]

84. Hosseinzade, A.; Sadeghi, O.; Naghdipour Biregani, A.; Soukhtehzari, S.; Brandt, G.S.; Esmaillzadeh, A. Immunomodulatory effects of flavonoids: Possible induction of T CD4+ regulatory cells through suppression of mTOR pathway signaling activity. *Front. Immunol.* 2019, 10, 51. [CrossRef] [PubMed]

85. Shaker, G.; Balasubramanian, S.; Hoda, M.; Rajagopalan, R. Inhibition of metastasis and angiogenesis in Hep-2 cells by wheatgrass extract—an in vitro and in silico approach. *Toxicol. Mech. Methods* 2018, 28, 205–218. [CrossRef] [PubMed]

86. Zhao, B.; Xiong, Y.; Zhang, Y.; Jia, L.; Zhang, W.; Xu, X. Rutin promotes osteogenic differentiation of periodontal ligament stem cells through the GPR30-mediated PI3K/AKT/mTOR signaling pathway. *Exp. Biol. Med.* 2020, 245, 552–561. [CrossRef] [PubMed]

87. Sun, J.; Wang, H.; Liu, B.; Shi, W.; Shi, J.; Zhang, Z.; Xing, J. Rutin attenuates H2O2-induced oxidation damage and apoptosis in Leydig cells by activating PI3K/Akt signal pathways. *Biomed. Pharmacother.* 2017, 88, 500–506. [CrossRef]

88. Talebi, H.; Farahpour, M.R.; Hamishehkar, H. The effectiveness of Rutin for prevention of surgical induced endometriosis development in a rat model. *Sci. Rep. 2021*, 11, 1–7. [CrossRef]

89. Wu, F.; Chen, J.; Fan, L.M.; Liu, K.; Zhang, N.; Li, S.W.; Zhu, H.; Gao, H.C. Analysis of the effect of rutin on GSK-3β and TNF-α expression in lung cancer. *Exp. Med.* 2019, 14, 127–130. [CrossRef] [PubMed]

90. Thabet, N.M.; Moustafa, E.M. Protective effect of rutin against brain injury induced by acrylamide or gamma radiation: Role of PI3K/AKT/GSK-3β/NRF-2 signalling pathway. *Arch. Physiol. Biochem.* 2018, 124, 185–193. [CrossRef] [PubMed]

91. Lins, T.L.B.G.; Gouveia, B.B.; Barberino, R.S.; Silva, R.L.S.; Monte, A.P.O.; Pinto, J.G.C.; Campinho, D.S.P.; Palheta, R.C.; Matos, M.H.T. Rutin prevents cisplatin-induced ovarian damage via antioxidant activity and regulation of PTEN and FOXO3a phosphorylation in mouse model. *Reprod. Toxicol.* 2020, 98, 209–217. [CrossRef] [PubMed]

92. Chattopadhayay, D.; Thirumurugan, K. Longevity-promoting efficacies of rutin in high fat diet fed *Drosophila melanogaster*. *Biogerontology* 2020, 21, 653–668. [CrossRef] [PubMed]

93. Crino, P.B. mTOR: A pathogenic signaling pathway in developmental brain malformations. *Trends Mol. Med.* 2011, 17, 734–742. [CrossRef] [PubMed]

94. Bruning, A. Inhibition of mTOR signaling by quercetin in cancer treatment and prevention. *Anticancer Agents Med. Chem.* 2013, 13, 1025–1031. [CrossRef] [PubMed]

95. Bose, S.; Banerjee, S.; Mondal, A.; Chakraborty, U.; Pumarol, J.; Croley, C.R.; Bishayee, A. Targeting the JAK/STAT signaling pathway using phytochemicals for cancer prevention and therapy. *Cells* 2020, 9, 1451. [CrossRef]

96. Guiterrez-Hoya, A.; Soto-Cruz, I. Role of the JAK/STAT pathway in cervical cancer: Its relationship with HPV E6/E7 oncoproteins. *Arch. Physiol. Biochem.* 2018, 185–193. [CrossRef] 

97. Qureshy, Z.; Johnson, D.E.; Grandis, J.R. Targeting the JAK/STAT pathway in solid tumors. *J. Cancer Metastasis Treat.* 2020, 6, 27. [PubMed]

98. Oh, H.; Park, S.H.; Kang, M.K.; Kim, Y.H.; Lee, E.J.; Kim, D.Y.; Kang, Y.H. Asaronic acid attenuates macrophage activation toward M1 phenotype through inhibition of NF-κB pathway and JAK-STAT signaling in glucose-loaded murine macrophages. *J. Agric. Food Chem.* 2019, 67, 10069–10078. [CrossRef]

99. Mohan, C.D.; Rangappa, S.; Preetham, H.D.; Chandra, N.S.; Gupta, V.K.; Basappa, S.; Sethi, G.; Rangappa, K.S. Targeting STAT3 signaling pathway in cancer by agents derived from Mother Nature. *Semin. Cancer Biol.* 2020, in press. [CrossRef]

100. Selloum, L.; Bouriche, H.; Tigrine, C.; Boudoukh, C. Anti-inflammatory effect of rutin on rat paw oedema, and on neutrophils chemotaxis and degranulation. *Exp. Toxicol. Pathol.* 2003, 54, 313–318. [CrossRef] [PubMed]

101. Fan, J.J.; Hsu, W.H.; Lee, K.H.; Chen, K.C.; Lin, C.W.; Lee, Y.L.; Ko, T.P.; Lee, L.T.; Lee, M.T.; Chang, M.S.; et al. Dietary flavonoids luteolin and quercetin inhibit migration and invasion of squamous carcinoma through reduction of Src/Stat3/S100A7 signaling. *Antioxidants* 2019, 8, 557. [CrossRef] [PubMed]
102. Nouri, Z.; Fakhr, S.; Nouri, K.; Wallace, C.E.; Farzaei, M.H.; Bishayee, A. Targeting multiple signaling pathways in cancer: The rutin therapeutic approach. *Cancers* 2020, 12, 2276. [CrossRef] [PubMed]

103. Choi, K.S.; Kundu, J.K.; Chun, K.S.; Na, I.K.; Surh, Y.J. Rutin inhibits UVB radiation-induced expression of COX-2 and iNOS in hairless mouse skin: p38 MAP kinase and JNK as potential targets. *Arch. Biochem. Biophys.* 2014, 559, 38–45. [CrossRef]

104. Arend, R.C.; Londono-Joshi, A.I.; Straughn, J.M., Jr.; Buchsbaum, D.J. The Wnt/β-catenin pathway in ovarian cancer: A review. *Gynecol. Oncol.* 2013, 131, 772–779. [CrossRef] [PubMed]

105. Khalaf, A.M.; Fuentes, D.; Morshid, A.I.; Burke, M.R.; Kaseb, A.O.; Hassan, M.; Hazde, J.D.; Elsayes, K.M. Role of Wnt/β-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance. *J. Hepatocell Carcinoma* 2018, 5, 61–73. [CrossRef] [PubMed]

106. Misra, U.K.; Pizzo, S.V. Modulation of the unfolded protein response in prostate cancer cells by antibody-directed against the β-carboxyl-terminal domain of GRP78. *Phytochem. Lett.* 2015, 10, 115–128. [CrossRef]

107. Santos, B.L.; Silva, A.R.; Pitanga, B.P.S.; Sousa, C.S.; Grangeiro, M.S.; Fragomeni, B.O.; Coelho, P.L.C.; Oliveira, M.N.; Menezes Filho, N.J.; Costa, M.F.; et al. Antiproliferative, proapoptotic and morphogenic effects of the flavonoid rutin on human glioblastoma cells. *Food Chem.* 2011, 127, 404–411. [CrossRef] [PubMed]

108. Schulz, G.B.; Elezkurtaj, S.; Börding, T.; Karl, A.; Horst, D. Therapeutic and prognostic implications of NOTCH and MAPK signaling in bladder cancer. *Cancer Sci.* 2021, 112, 1987–1996. [CrossRef] [PubMed]

109. Semwal, R.; Joshi, S.K.; Semwal, R.B.; Semwal, D.K. Health benefits and limitations of rutin-A natural flavonoid with high nutraceutical value. *Phytochem. Lett.* 2016, 23, 98–107. [CrossRef] [PubMed]

110. Nafees, S.; Rashid, S.; Ali, N.; Hasan, S.K.; Sultana, S. Rutin ameliorates cyclophosphamide induced oxidative stress and inflammation in Wistar rats: Role of NFκB/MAPK pathway. *Chem. Biol. Interact.* 2015, 231, 98–107. [CrossRef] [PubMed]

111. Choi, K.S.; Kundu, J.K.; Chun, K.S.; Na, H.K.; Surh, Y.J. Rutin inhibits UVB radiation-induced expression of COX-2 and iNOS in skin. *Arch. Biochem. Biophys.* 2009, 484, 579–591. [CrossRef] [PubMed]

112. Santos, B.L.; Silva, A.R.; Pitanga, B.P.S.; Sousa, C.S.; Grangeiro, M.S.; Fragomeni, B.O.; Coelho, P.L.C.; Oliveira, M.N.; Menezes Filho, N.J.; Costa, M.F.; et al. Anti-proliferative, pro-apoptotic and morphogenetic effects of the flavonoid rutin on human glioblastoma cells. *Food Chem.* 2011, 127, 404–411. [CrossRef] [PubMed]

113. Tatipamula, V.B.; Kukavica, B. Phenolic compounds as antidiabetic, anti-inflammatory, and anticancer agents and improvement of their bioavailability by liposomes. *Cell Biochem. Funct.* 2021, [published online ahead of print, 9 September 2021]. [CrossRef] [PubMed]

114. Javed, Z.; Ullah, M.; Ashfaq, H.A.; Shah, A.H.; Shahzad, M.; Bilal, M.; Sumrin, A.; Bashir, H.; Siddiqi, M.H.; Sadia, H. Role of MicroRNA in endometrial carci noma. *Adv. Life Sci.* 2016, 4, 08–13. [CrossRef] [PubMed]

115. Ozbey, U.; Attar, R.; Romero, M.A.; Alhewairini, S.S.; Afshar, B.; Sabitaleivych, U.Y.; Hanna-Wakim, L.; Ozcelik, B.; Farooqi, A.A. Apigenin as an effective anti cancer natural product: Spotlight on TRAIL, WNT/β-catenin, JAK-STAT pathways, and microRNAs. *J. Cell Biochem.* 2019, 120, 1060–1067. [CrossRef] [PubMed]

116. Trachootham, D.; Alexandre, J.; Huang, P. Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach? *Nat. Rev. Drug Discov.* 2009, 8, 579–591. [CrossRef] [PubMed]

117. Nafees, S.; Rashid, S.; Ali, N.; Hasan, S.K.; Sultana, S. Rutin ameliorates cyclophosphamide induced oxidative stress and inflammation in Wistar rats: Role of NFκB/MAPK pathway. *Chem. Biol. Interact.* 2015, 231, 98–107. [CrossRef] [PubMed]

118. Santos, B.L.; Silva, A.R.; Pitanga, B.P.S.; Sousa, C.S.; Grangeiro, M.S.; Fragomeni, B.O.; Coelho, P.L.C.; Oliveira, M.N.; Menezes Filho, N.J.; Costa, M.F.; et al. Antiproliferative, pro-apoptotic and morphogenetic effects of the flavonoid rutin on human glioblastoma cells. *Food Chem.* 2011, 127, 404–411. [CrossRef] [PubMed]

119. Khalaf, A.M.; Fuentes, D.; Morshid, A.I.; Burke, M.R.; Kaseb, A.O.; Hassan, M.; Hazde, J.D.; Elsayes, K.M. Role of Wnt/β-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance. *J. Hepatocell Carcinoma* 2018, 5, 61–73. [CrossRef] [PubMed]

120. Choi, K.S.; Kundu, J.K.; Chun, K.S.; Na, H.K.; Surh, Y.J. Rutin inhibits UVB radiation-induced expression of COX-2 and iNOS in skin. *Arch. Biochem. Biophys.* 2009, 484, 579–591. [CrossRef] [PubMed]

121. Trachootham, D.; Alexandre, J.; Huang, P. Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach? *Nat. Rev. Drug Discov.* 2009, 8, 579–591. [CrossRef] [PubMed]

122. Javed, Z.; Ullah, M.; Ashfaq, H.A.; Shah, A.H.; Shahzad, M.; Bilal, M.; Sumrin, A.; Bashir, H.; Siddiqi, M.H.; Sadia, H. Role of MicroRNA in endometrial carci noma. *Adv. Life Sci.* 2016, 4, 08–13. [CrossRef] [PubMed]

123. Ozbey, U.; Attar, R.; Romero, M.A.; Alhewairini, S.S.; Afshar, B.; Sabitaleivych, U.Y.; Hanna-Wakim, L.; Ozcelik, B.; Farooqi, A.A. Apigenin as an effective anti cancer natural product: Spotlight on TRAIL, WNT/β-catenin, JAK-STAT pathways, and microRNAs. *J. Cell Biochem.* 2019, 120, 1060–1067. [CrossRef] [PubMed]

124. Chattopadhyay, B.; Banik, N.L.; Ray, S.K. miR-138 overexpression is more powerful than hTERT knockdown to potentiate apigenin effects in neuroblastoma in vitro and in vivo. *Exp. Cell Res.* 2021, 319, 1575–1585. [CrossRef] [PubMed]

125. Cannataro, R.; Fazio, A.; La Torre, C.; Caroile, M.C.; Cione, E. Polyphenols in the Mediterranean Diet: From Dietary Sources to microRNA Modulation. *Antioxidants* 2021, 10, 328. [CrossRef] [PubMed]

126. Zhou, M.; Zhang, G.; Hu, J.; Zhu, Y.; Lan, H.; Shen, X.; Lv, Y.; Huang, L. Rutin attenuates Sorafenib-induced Chemoresistance and Autophagy in Hepatocellular Carcinoma by regulating BANCR/miRNA-590-5P/OLR1 Axis. *Int. J. Biol. Sci.* 2021, 17, 3595–3607. [CrossRef] [PubMed]

127. Li, Q.; Xu, D.; Gu, Z.; Li, T.; Huang, P.; Ren, L. Rutin restrains the growth and metastasis of mouse breast cancer cells by regulating the microRNA-129-1-3p-mediated calcium signaling pathway. *J. Biochem. Mol. Toxicol.* 2021, 35, e22794. [CrossRef] [PubMed]

128. Qin, M.; Li, Q.; Wang, Y.; Li, T.; Gu, Z.; Huang, P.; Ren, L. Rutin treats myocardial damage caused by pirarubicin via regulating miR-22-5p-regulated RAPI/ERK signaling pathway. *J. Biochem. Mol. Toxicol.* 2021, 35, e22615. [CrossRef] [PubMed]